skip to main content

Neonatal Lupus Prevention — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardSLE & Antiphospholipid SyndromeNeonatal Lupus PreventionSCE Rheumatology

A 28-year-old woman with quiescent SLE and anti-Ro/SSA antibodies is planning pregnancy. Her previous pregnancy was complicated by complete fetal atrioventricular block attributed to cardiac neonatal lupus. Which statement best describes the recurrence risk and the evidence-based approach to secondary prevention?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — The recurrence risk is about 18%; hydroxychloroquine 400 mg/day by 10 weeks and continued in pregnancy can reduce it by over half.

After one anti-Ro/SSA-associated affected pregnancy, the historical recurrence risk of fetal second- or third-degree congenital heart block is approximately 18%, rather than the 1–2% risk in a first anti-Ro-exposed pregnancy. In the prospective PATCH study, hydroxychloroquine 400 mg/day commenced by completion of gestational week 10 and continued throughout pregnancy was associated with a recurrence rate of 7.4%, reducing the historical risk by more than half. The evidence is not from a randomised placebo-controlled trial, but hydroxychloroquine currently has the strongest evidence for secondary prevention and is compatible with UK pregnancy prescribing practice. Prophylactic dexamethasone or prednisolone is not established to prevent heart block and carries maternal–fetal toxicity. Intravenous immunoglobulin has not demonstrated comparable preventive efficacy. The previous affected pregnancy therefore materially increases risk and warrants specialist preconception and fetal-medicine management.

Reference: Izmirly PM et al. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers (PATCH), 2020. https://pubmed.ncbi.nlm.nih.gov/32674792/